Combined genetic and high-throughput strategies for the molecular diagnosis of inherited retinal dystrophies by Castro-Miró, Marta de et al.
Combined Genetic and High-Throughput Strategies for
Molecular Diagnosis of Inherited Retinal Dystrophies
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Abstract
Most diagnostic laboratories are confronted with the increasing demand for molecular diagnosis from patients and families
and the ever-increasing genetic heterogeneity of visual disorders. Concerning Retinal Dystrophies (RD), almost 200
causative genes have been reported to date, and most families carry private mutations. We aimed to approach RD genetic
diagnosis using all the available genetic information to prioritize candidates for mutational screening, and then restrict the
number of cases to be analyzed by massive sequencing. We constructed and optimized a comprehensive cosegregation RD-
chip based on SNP genotyping and haplotype analysis. The RD-chip allows to genotype 768 selected SNPs (closely linked to
100 RD causative genes) in a single cost-, time-effective step. Full diagnosis was attained in 17/36 Spanish pedigrees,
yielding 12 new and 12 previously reported mutations in 9 RD genes. The most frequently mutated genes were USH2A and
CRB1. Notably, RD3–up to now only associated to Leber Congenital Amaurosis– was identified as causative of Retinitis
Pigmentosa. The main assets of the RD-chip are: i) the robustness of the genetic information that underscores the most
probable candidates, ii) the invaluable clues in cases of shared haplotypes, which are indicative of a common founder effect,
and iii) the detection of extended haplotypes over closely mapping genes, which substantiates cosegregation, although the
assumptions in which the genetic analysis is based could exceptionally lead astray. The combination of the genetic
approach with whole exome sequencing (WES) greatly increases the diagnosis efficiency, and revealed novel mutations in
USH2A and GUCY2D. Overall, the RD-chip diagnosis efficiency ranges from 16% in dominant, to 80% in consanguineous
recessive pedigrees, with an average of 47%, well within the upper range of massive sequencing approaches, highlighting
the validity of this time- and cost-effective approach whilst high-throughput methodologies become amenable for routine
diagnosis in medium sized labs.
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Introduction
Retinal dystrophies (RD) are a group of more than 25 genetic
visual disorders [1]. Although RDs rank among mendelian rare
diseases, taken together, they occur at an estimated prevalence of
1–2 patients per 1000 individuals. In fact, the most frequent form
of RD, retinitis pigmentosa (RP), affects 1.5 million individuals
worldwide [2]. The clinical traits underlying these disorders
disturb from the macular region (central vision) to the outlying
retinal area (peripheral vision). In addition, at least 30 different
syndromes (such as Usher and Bardet-Biedl) share some of these
phenotypic alterations [3,4]. On the genetic side, more than 5000
mutations in almost 200 genes are causative of retinal dystrophies
so far [1,5,6]. Yet, around 35% of the cases remain unassigned [7].
The extreme heterogeneity of RDs at the clinical and genetic levels
hinders the accurate clinical assessment, patient management, and
genetic counseling. Within this context, molecular diagnosis,
however challenging, is instrumental to improve the diagnosis
and prognosis of RDs and guide future therapies [7–9].
Currently, the most demanding issue in RD molecular diagnosis
is the prioritization of methodological strategies, where the main
parameters to be balanced are cost, time and yield. These
parameters strongly depend on phenotypic clinical assessment,
pedigree information, sample availability and methodological
resources. Most genetic laboratories resort to direct mutational
screening when the clinical traits and/or the genetic information
associated to the disease limit the number of candidates to be
analyzed. Unfortunately, this is not a common case for RDs, and
this type of analysis would imply screening more than 1500 exons.
The search for an alternative cost-effective approach is mainly
being performed using high-throughput platforms, in particular
massive sequencing, which require powerful and sophisticated
bioinformatics tools for analyzing and filtering the data [10,11].
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To improve diagnosis, we have focused on a comprehensive
strategy based on the clinical phenotype and all available genetic
data prior to either analyze a reduced manageable number of
candidate genes or resort to massive sequencing. We have
generated and optimized a SNP-based chip for haplotype
cosegregation analysis [12,13] to genotype 7–10 SNP markers of
one hundred genes associated to the most prevalent RDs: Cone
Dystrophies (CD), Cone-Rod Dystrophies (CRD), Congenital
Stationary Night Blindness (CSNB), Leber Congenital Amaurosis
(LCA), Macular Degeneration (MD) and RP. Based on this
methodology, a multi-tiered approach has been devised to cost-
effectively diagnose [14] a panel of 36 Spanish families with non-
syndromic retinal dystrophies plus 5 patients with Usher’s
syndrome. As a result, we have identified the pathogenic mutation
of 17 out of the 36 families, and 3 of the 5 isolated Usher patients,
overall reporting 14 novel mutations. After the RD-chip analysis
discarded all known RD genes, Whole Exome Sequencing (WES)
was undertaken in two pedigrees. The pathogenic mutations were
unexpectedly identified in two RD candidates, which had been
previously discarded as non-cosegregating on the basis of
homozygosity by descent in consanguineous families, and infre-
quent recombination of closely mapping SNPs.
Methods
Patients
Thirty-six Spanish families diagnosed with RP, LCA, CRD or
CD plus 5 isolated Usher’s syndrome patients were recruited for
this study. Written informed consent from the patients and
relatives was obtained following the tenets of the Declaration of
Helsinki. Patient recruitment and sample collection procedures
had been previously approved by the Bioethics Committee of the
University of Barcelona (Barcelona, Spain). Peripheral blood DNA
was obtained using the MoleStrips DNA Blood kit with the
GeneMole instrument (Mole Genetics, Mole, Lysaker, Norway).
DNA from Spanish control individuals was obtained from
peripheral blood using the same methodology.
SNP Selection
The RD chip for the molecular diagnosis of Mendelian non-
syndromic retinal dystrophies was an optimized version of a
previous cosegregation chip for RP-LCA disorders [12,13]. Seven
to ten SNPs were selected for each candidate (100 genes in total),
and genotyped on a customized Golden Gate Genotyping Assay
(Illumina). The SNPs were selected following: i) high informativity
according to SNPbrowser Software Version 4.0.1 and dbSNP
database (www.nlm.nih.gov/projects/SNP/); ii) physical location
(covering upstream, intragenic and downstream regions); iii)
inclusion in different haplotypic blocks. The genes analyzed by
this RD chip are listed by chromosome position in Figure 1. In
addition, some common mutations in ABCA4, CERKL, COL8A2,
CRB1, LRP5, NR2E3, PRPF31, RHO and USH2A, were included
for direct genotyping.
High-throughput SNP Genotyping
One microgram of sample DNA (at 20 ng/ml) was laid in 96-
well plates. SNPs were genotyped using the Golden Gate Array
(Illumina) platform following the instructions, protocol and
software provided by the manufacturers. Haplotype and cose-
gregation analyzes were performed by hand from the raw data
genotypes.
Mutational Screening
In Usher syndrome samples, where a major causative gene is
involved, the Arrayed Primer Extension (APEX) approach plus
direct gene sequencing was the molecular diagnosis procedure of
selection. In all other cases, cosegregation analysis with the RD-
chip allowed to highlight the best candidates for mutational
screening. All the exons and exon–intron boundaries of selected
genes were directly screened for mutations in each patient.
Genomic DNA was amplified, purified on High Pure 96 UF
Cleaning Plates (Roche) and sequenced using the BigDye v3.1 kit
(Applied Biosystems, Inc.) in the ABI PRISM 3730 DNA
sequencer (Applied Biosystems, Inc.).
All missense changes identified were verified in control
population using the dbSNP database (Build 137, www.ncbi.nlm.
nih.gov/projects/SNP/), the 1000 Genomes Project data (http://
browser.1000genomes.org/index.html), and ESP6500 data of the
National Heart, Lung, and Blood Institute GO Exome Sequencing
Project (http://evs.gs.washington.edu/EVS). To validate unre-
ported missense genetic variants, over one hundred matched
controls were analyzed to discard rare non-pathogenic polymor-
phisms restricted to the Spanish population.
Bioinformatic Analyses
All the sequences were analyzed using the sequence assembly
software Seqman (DNAStar, Madison, WI) and aligned to the
reference gene sequence (Genome Reference Consortium human
genome build 37, human genome 19).
The pathogenicity of all new missense changes identified in
patients was evaluated using the in silico predictors SIFT (http://
sift.jcvi.org/[15]) and PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph2/[16]). When the putative mutations affected splice sites,
the splicing site score values of the wild-type and variant sequences
were predicted online with NetGene2 (http://www.cbs.dtu.dk/
services/NetGene2/[17,18]), Human Splicing Finder [19], and
MaxEntScan (http://www.umd.be/HSF/[20]) prediction servers.
Whole-Exome Sequencing
Genomic DNA from peripheral blood was prepared using the
QIAamp DNA Blood Maxi Kit (Qiagen). Exome capture was
performed at the CNAG using SureSelectXT All Exome v4 kit
(Agilent), following the manufacturer’s protocol. Libraries were
sequenced on a HiSeq2000 (Illumina) to at least 80x average
coverage of the target region.
Reads were aligned to the human reference genome build
GRCh37 (hg19) using the Burrows-Wheeler Aligner (BWA) [21]
in family E5 and GEMMapper [22] in family 9RE. Mapped reads
were filtered (leaving only those mapping in unique genomic
positions with enough quality), sorted and indexed with SAMtools
(version 0.1.18) [23]. Identification of single nucleotide variants
and Indels was performed using GATK standard hard filtering
parameters [24] (family E5) or SnpEff [25] (family 9RE). In house
Perl scripts were used to select the variants shared by all affected
individuals, predicted to produce a high or moderate impact,
including intron-exon junctions, non-annotated variants (synony-
mous, non-synonymous, and non-sense mutations) in coding
regions, or short coding insertions or deletions. Variants mapping
to the candidate genes were selected for further validation. For the
final WES report the VARIANT [26] annotation tool provided
the putative functional consequence, as well as other additional
relevant information of the identified variants for the final
candidate gene selection.
Combined Strategies for RD Molecular Diagnosis
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Figure 1. Genes included in the RD-chip. The RD-chip contains the most relevant RD genes at the time of the array design (100 genes). Genes are
listed by chromosome and physical location. The interval between the first and last genotyped SNP is shown as ‘‘Covered region’’ (the chromosome
position is based on human reference sequence NCBI 36/hg18). Colored boxes indicate association with particular retinal dystrophies. CD/CRD: Cone
or Cone-Rod Dystrophy; CSNB: Congenital Stationary Night Blindness; LCA: Leber Congenital Amaurosis; MD: Macular Degeneration; RP: Retinitis
Pigmentosa; OR: Other Retinopathies.
doi:10.1371/journal.pone.0088410.g001
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RT-PCR Expression Analysis
Blood samples from patients, relatives and unrelated controls
were mixed with an RNA stabilizer solution (RNALater; Ambion)
in a 1:4 ratio. Total RNA was obtained from 3 ml of blood using
the RiboPure-Blood Kit (Ambion, Austin, TX), and retrotran-
scribed using the Transcriptor High Fidelity cDNA Synthesis Kit
(Roche Applied Science, Indianapolis, IN) with a mixture of
random hexamers and oligo(dT)18, according to the manufactur-
er’s instructions. RPGRIP1 and G3PDH (used as control)
transcripts were amplified using specific exon primers and the
GoTaq Flexi DNA polymerase (Promega, Fitchburg, WI) in a final
volume of 50 ml. The G3PDH PCR conditions were: denaturation
for 5 min at 94uC followed by 35 cycles of 20 s at 94uC, 30 s at
60uC, and 1 min at 72uC, using 2 ml of cDNA. For RPGRIP1,
primers were located in exons 14 and 16, and the PCR conditions
were: denaturation for 5 min at 94uC followed by 38 cycles of 20 s
at 94uC, 30 s at 60uC and 40 s at 72uC, using 5 ml of cDNA.
Amplified bands were excised, purified from the gel using the
Expin GeneAll Gel SV kit (GeneAll) following the manufacturer’s
protocol, and sequenced.
Plasmid Constructions and Expression Assay
The reconstructed RPGRIP1 minigene encompassed exons 12 to
18, plus at least 200 bp of each intron-exon boundary, after
amplification of genomic DNA from patient 1 of the 59RE
pedigree (heterozygote for the c.2367+23del mutation). The
minigene was cloned in-frame at the C-terminus of the HA
epitope into the pcDNA3.1 expression vector. Wild-type and
mutated clones were confirmed by sequencing.
HEK293 cells were seeded on 12-well plates (46105 cells/well)
and grown in DMEM (Invitrogen, Barcelona, Spain) supplement-
ed with 10% of fetal bovine serum. After 12 hours, cells were
transiently transfected with, either the pcDNA3.1-wild type (wt)
RPGRIP1 minigene, the pcDNA3.1-mut RPGRIP1 minigene
(containing the c.2367+23del mutation), or the empty vector
(Clontech-BD), using Lipofectamine 2000 (Invitrogen). Forty-eight
hours after transfection, cells were collected, lysed, and total
mRNA was used for RT-PCR (same protocol as above). RPGRIP1
cDNA amplification was performed using primers of exons 15 and
18 as follows: denaturation for 5 min at 94uC, followed by 35
cycles of 20 s at 94uC, 30 s at 62uC, and 1 min 30 s at 72uC, using
1 ml of cDNA. G3PDH amplification was used as a control.
Results
Classification of the Patients According to Phenotype
and Family Information
Our initial cohort comprised 41 families, 36 affected with non-
sydromic RDs and 5 affected by Usher syndrome type II. We
attained full diagnosis for 22 of them, whose pedigrees are
displayed in Figure 2. Cosegregation with the novel mutated alleles
identified is shown in Figure S1.
Analysis of Usher Syndrome Cases
Usher syndrome is characterized by specific phenotypic traits
that allow a clear clinical characterization in three main forms,
being USH II the most frequent type (between half and two thirds
of all cases), and USH2A the major causative gene (75–80% of
USH II cases) [27]. Our cohort had 5 USH II cases as isolated
patients or small pedigrees, which when directly tested for
described mutations in USH2A (Asper Biotech), only 4 out of 10
mutated alleles were identified, all in heterozygosis. As no
complete molecular diagnosis was achieved, direct mutational
screening of all USH2A exons was then undertaken, prioritizing
the analysis of exons where reported mutations cluster. Overall,
three of the five patients (pedigrees shown in Figure 2) were
completely diagnosed, with 3 missense mutations identified:
c.1751G.T in heterozygosis (p.C584F), c.10636G.A in homo-
zygosis (p.G3546R), and c.12574C.T in heterozygosis
(p.R4192C) (Table 1 A). The pathogenicity of the two novel
variants, p.C584F and p.R4192C, was supported by the PolyPhen
and SIFT algorythms (Table 2). In the remaining two patients only
one mutated allele was identified (Table 1 A).
Genotyping of RD Families
Contrary to Usher syndrome, most RDs show high clinical and
genetic heterogeneity, which greatly hampers molecular diagnosis.
Our approach was to use genetic information and cosegregation
analysis to decrease the number of candidate genes for mutational
screening. When pedigrees were available, the use of an
automated and robust SNP-based genotyping microarray greatly
diminished the number of candidates. To this aim, 36 families
(with at least four available samples) affected with retinal
dystrophies (Retinitis Pigmentosa, Leber Congenital Amaurosis,
Cone-rod Dystrophy or Cone Dystrophy) were analyzed with our
optimized in house RD-chip that genotyped 768 SNP markers
spanning the 100 most prevalent RD genes reported at that
moment (Figure 1). Six families showed autosomal dominant
inheritance and a large number of affected individuals; twenty-
nine were autosomal recessive pedigrees with a low number of
affected members, and the remaining two were compatible with
X-linked inheritance.
After RD-chip genotyping, haplotypes were constructed for
each family to assess cosegregation under the presumed inheri-
tance pattern. In pedigrees where 90 to 99% of candidates were
discarded, direct mutational screening was performed in the
remaining non-excluded genes. For each case, the candidates were
prioritized according to previous gene assignment to: 1) the same
clinical diagnosis and mendelian pattern; 2) a closely related
retinal dystrophy with the same inheritance pattern; 3) the same
clinical phenotype irrespective of the inheritance pattern, and
finally 4) the remaining RD candidates.
This approach allowed us to identify the pathogenic mutation in
17 families out of 36 (47,2%), depicted in Figure 2:2/2 in X-linked
families, 6/18 of recessive non-consanguineous families (33,3%),
8/10 recessive consanguineous families (80%) and 1/6 of
dominant families (16,6%).
Inferred Haplotypes and Subsequent Mutation Screening
of the Prioritized Candidates in X-linked and Dominant
Pedigrees
The genotyping results for each family were first analyzed under
the most probable mendelian pattern of inheritance to exclude
non-cosegregating genes and prioritize the remaining candidates.
The final results are presented by family and summarized in
Table 1 B.
Seven pedigrees were compatible with an autosomal dominant
(ad) pattern, but one (11NCE) could also be explained by an X-
linked inheritance, as all affected women showed a less severe
phenotype. In this case, the haplotypes were first analyzed under a
X-linked hypothesis (see below). Of the six AD families, only 2
(6ORG and 2NCE) were amenable for mutational screening,
while in the rest more than 10 candidates remained. Indeed, in
dominant diseases a large number of samples is required to attain
genetic informativity, which seldom occurs. In family 6ORG, the
RD-chip highlighted seven candidates, three of them responsible
for adRP: SEMA4A, SNRNP200 and TOPORS. We prioritized the
Combined Strategies for RD Molecular Diagnosis
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Figure 2. Spanish pedigrees diagnosed in this study. Families were categorized as arUSH II, arRP, adRP, XL-RP, arLCA, arCRD and adCD
according to mendelian pattern of inheritance and phenotype. Bold numbers indicate samples available for analysis.
doi:10.1371/journal.pone.0088410.g002
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analysis of SNRNP200, as the cosegregating haplotype extended to
three neighbouring RD genes (CNNM4, CNGA3, MERTK), overall
covering more than 16 Mb (Figure 1). Direct exonic sequence
revealed a novel missense mutation in SNRNP200, c.2042G.T
(p.R681L) (Table 1 B) in a codon also mutated in other adRP cases
(c.2041C.T, p.R681C and c.2042G.A, p.R681H) [28]. Bioin-
formatics analysis showed that this residue was highly evolutionary
conserved (data not shown) and predicted a damaging effect
(Table 2). Moreover, none of the healthy siblings did carry the
pathogenic variant, supporting its pathogenicity. In family 2NCE,
after the RD chip analysis, ten candidates remained. Extended
haplotypes with neighbouring RD genes decreased the number of
candidates to five. Unfortunately, no mutation was found in any
candidate (the pedigree is not included in Figure 2).
Table 1. Summary of the diagnosed families in this study.
A) USH II families
Family Phenotype Inheritance Gene Nucleotide change Protein change Zygosity References
40ORG Usher II recessive USH2A c.1751G.T p.C584F Het [a]
c.2299delGb p.E767Sfs*20 Het [50]
54RE Usher II recessive USH2A c.10636G.A p.G3546R Hom [34]
5ORG Usher II recessive USH2A c.9799T.Cb p.C3267R Het [33]
c.12574C.T p.R4192C Het [a]
56RE Usher II recessive USH2A c.2299delGb p.E767Sfs*20 Het [50]
n.i n.i
94RE Usher II recessive USH2A c.2299delGb p.E767Sfs*20 Het [50]
n.i n.i
B) Families analized by the RD-xip with identified mutations (sorted by gene).
12ORG RP recessive CRB1 c.1702C.T p.H568Y Hom [a]
10RE LCA recessive CRB1 c.3749+2_3749+3del splicing Homo/Het [a]
c.2843G.A p.C948Y Het [30]
23NCE RP recessive CRB1 c.2290C.T p.R764C Hom [30]
25NCE RP recessive CRB1 c.2843G.A p.C948Y Hom [30]
T5 RP recessive CRB1 c.2843G.A p.C948Y Hom [30]
17NCE RP recessive MERTK c.2189+1G.T splicing Hom [31]
22NCE RP recessive PROM1 c.1984-1G.T splicing Hom [a]
83RE RP recessive RD3 c.259A.G p.K87E Hom [a]
11NCE RP X-linked RP2 c.409_411del p.I137del Hemi [29]
20NCE RP X-linked RP2 All gene deletion Hemi [a]
59RE LCA recessive RPGRIP1 c.895_896del p.E299Sfs*21 Het [a]
c.2367+23delc intronic Het [a]
6ORG RP dominant SNRNP200 c.2042G.T p.R681L Het [a]
18NCE RP recessive USH2A c.2276G.T p.C759F Het [32]
c.9799T.C p.C3267R Het [33]
21NCE RP recessive USH2A c.1434G.C p.E478D Het [51]
c.2276G.T p.C759F Het [32]
75RE RP recessive USH2A c.2209C.T p.R737X Het [52]
c.8693A.C p.Y2898S Het [a]
5NCE RP recessive USH2A c.652-2A.G splicing Het [a]
c.2276G.T p.C759F Het [32]
93RE CRD recessive ABCA4 c.3988G.T p.E1330X Het [a]
c.6410G.A p.C2137Y Het [a]
C) Families with identified mutations by WES
9RE CD dominant GUCY2D c.2747T.C p.I916T Het [a]
E5 RP recessive USH2A c.2167+5G.A splicing Het [53]
c.4325T.C p.F1442S Het [35]
c.7364G.A p.W2455X Het [a]
For each family, the phenotype, inheritance model, the altered gene, the identified mutation, the homozygosity/heterozygosity state, and the reference of previously
described mutations are indicated. [a] This study, bMutations previously identified by APEX cUnknown pathogenicity, n.i Not identified.
doi:10.1371/journal.pone.0088410.t001
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X-linked inheritance was assumed for 20NCE and 11NCE, the
latter being also compatible with AD inheritance. SNP genotyping
revealed a common deleted region comprising the full RP2 locus in
all male patients of 20NCE, clearly underscoring RP2 as the
disease-causing gene. Indeed, mutational screening confirmed the
deletion of the whole coding region. Concerning pedigree 11NCE,
the milder affectation of women -suggestive of an X-linked trait-,
added to the cosegregation of the RP2 haplotype, both pinpointed
this candidate for mutational screening. Exon sequencing identi-
fied a previously reported mutation, c.409_411del causing
p.I137del, in all the family patients (Table 1 B) [29].
Recessive Consanguineous Families
In five of ten known consanguineous families (10RE, 12ORG,
23NCE, T5, and 25NCE), CRB1 was the candidate of choice.
Prioritization was established based on either an extended
haplotype comprising the adjacent CFH locus in four pedigrees,
or a shared haplotype with a previously diagnosed family,
suggesting a founder effect.
The patient II.6 in the family 10RE (Figure 2) carried an
homozygous unreported deletion in the intron 9 splice donor site
of CRB1, c.3749+2_3749+3del, which ablated the splice signal.
This outcome was confirmed by in silico predictions (Table 3). His
nephew was a double heterozygote for this mutation plus a
frequent pathogenic variant, c.2843G.A p.C948Y [30].
In family 12ORG, all but four RD genes were discarded, of
those, CRB1 showed an extended haplotype. Direct sequencing
revealed a novel missense mutation in homozygosity, c.1702C.T
p.H568Y, whose pathogenicity was supported by in silico analyses
(Table 2). On the other hand, families 23NCE and T5 showed
homozygosity for the known missense mutations c.2290C.T
p.R764C, and c.2843G.A p.C948Y, respectively [30]. Of note,
the haplotype of family T5 affected members was also shared by
the patients of another family (25NCE). Subsequent sequencing
analysis of CRB1 confirmed the same causative mutation,
supporting common ancestry.
Family 83RE showed an extended haplotype spanning USH2A
and RD3. Given that the clinical diagnosis of the family was RP,
USH2A was prioritized for direct mutational screening but was
excluded after sequencing 72 exons. Screening of the RD3
candidate, previously reported only as a LCA-causative gene,
revealed a new missense mutation c.259A.G p.K87E in
homozygosity. In silico predictions supported its pathogenicity
(Table 2). Notably, this variant had been identified in 4 out of
13.002 control chromosomes (NHLBI Exome Sequencing Proj-
ect).
The consanguineous family 75RE was first analyzed assuming
homozygosity by descent, and under this assumption, all
candidates were discarded. However, if non-consanguinity was
assumed an extended haplotype spanning candidates USH2A and
RD3 emerged. Subsequent mutational screening of USH2A
identified two disease-causing mutations in the patients: the
reported nonsense c.2209C,T p.R737X and the novel missense
c.8693A.C p.Y2898S. The pathogenicity of the latter was fully
supported by in silico predictions (Table 2).
The non-discarded genes of family 17NCE were prioritized
according to: 1) cosegregation and phenotype, pointing to LRAT,
or 2) shared haplotype with a previously diagnosed Spanish family
in MERTK [31]. LRAT was discarded after sequencing of all exons,
whereas direct screening of MERTK exon 16 identified the
expected mutation c.2189+1G.T in homozygosis, again support-
ing a founder effect.
Two remaining families were not further considered due to the
lack of genetic informativity.
Recessive Non-consanguineous Families
After cosegregation analysis, three candidate genes remained in
the 22NCE family (PROM1, RP1 and TEAD1). Although
consanguinity had not been reported, the mutational screening
of PROM1 revealed a novel homozygous mutation, c.1984-1G.T,
which ablates the consensus acceptor splice site of intron 17. Its
pathogenicity was fully confirmed by in silico predictions (Table 3).
In family 59RE, seven candidate genes cosegregated, although
the clinical phenotype of the patients pointed RPGRIP1 and
TULP1 as the best candidates. TULP1 did not bear any mutation,
whereas two previously unreported variants in RPGRIP1 were
identified. The variant c.895_896del, p.E299Sfs*21, was clearly
pathogenic and produced a truncated protein. The other variant
was intronic, c.2367+23del, and the possible pathogenic effect was
unknown. In silico predictions for splice sites, splice enhancers and
silencers did not reveal any strong molecular alteration. Besides,
in vivo analysis of patient’s mRNAs was restrained by the RPGRIP1
low expression levels in blood. Finally, the transfection in cultured
cells of minigenes bearing either the WT or the variant sequence
did not conclusively support its pathogenicity. As the analysis of
434 control chromosomes identified this variant once, the c.2367+
23del variant could be presumably classified as a rare indel, and its
pathogenicity remains to be proved.
Table 2. Pathogenicity predictions for new missense
mutations.
SIFT PolyPhen-2
Gene Mutation Score Prediction Score Prediction
CRB1 p.H568Y 1 Tolerated 0,999 Probably damaging
GUCY2D p.I916T 0,002 Damaging 1 Probably damaging
RD3 p.K87E 0,01 Damaging 0,997 Probably damaging
SNRNP200 p.R681L 0 Damaging 1 Probably damaging
USH2A p.C584F 0 Damaging 1 Probably damaging
USH2A p.F1442S 0 Damaging 1 Probably damaging
USH2A p.Y2898S 0 Damaging 0,998 Probably damaging
USH2A p.R4192C 0 Damaging 0,998 Probably damaging
ABCA4 p.C2137Y 0 Damaging 1 Probably damaging
Dash(2) means no splice site predicted.
doi:10.1371/journal.pone.0088410.t002
Table 3. Pathogenicity predictions for new splicing
mutations.
NetGene2
(0–1)
MaxEnt
(score)
HSF
(0–100)
CRB1 wt 0,37 9,6 96,67
c.3749+2_3749+3del – – –
MERTK wt 0,86 5,58 86,8
c.2189+1G.T – – –
PROM1 wt 0 8,36 84,3
c.198421G.T – – –
USH2A wt 0,83 4,89 90,92
c.65222A.G – 0,56 –
doi:10.1371/journal.pone.0088410.t003
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Three families compatible with a recessive RP inheritance
(5NCE, 18NCE and 21NCE) showed cosegregation with 5–12
candidates, USH2A among them. Given that direct genotype of
mutations in the RD-chip had already detected a frequent USH2A
pathogenic allele c.2276G.T, p.C759F, in heterozygosis [32],
direct sequencing of the full coding sequence was undertaken.
Data revealed one novel pathogenic allele in family 5NCE, c.652-
2A.C, which ablates the acceptor splice site, and two reported
mutations c.9799T.C p.C3267R (18NCE) and c.1434G.C
p.E478D (21NCE); although the pathogenicity of this last variant
is still controversial [32–34].
Family 93RE whose clinical diagnosis was compatible with
either CRD or recessive Stargardt disease showed cosegregation
with GNAT2, ZNF513, OPA1, RP1L1 and ABCA4. Based on the
type of inheritance and phenotype, we prioritized the analysis of
GNAT2, ZNF513 and ABCA4. Two unreported mutations in
ABCA4 were identified, the nonsense c.3988G.T p.E1330X and
the missense c.6410G.A p.C2137Y variants. In silico predictions
by PolyPhen2 and SIFT of the latter supported its pathogenicity
(Table 2).
WES Families
After exclusion with the chip of the one hundred RD
candidates, WES was undertaken in suitable remaining families.
Concerning family E5, most recessive RD genes were discarded
under the assumption of claimed consanguinity (I.1 and I.2), and
the rest of candidates was excluded by Sanger sequencing. WES
was then undertaken for patients II.4 and III.2 (Figure 2).
Unexpectedly, one novel (c.7364G.A) and one recently reported
mutation (c.4325T.C) [35] in USH2A were identified in patient
II.4, whereas his affected son (patient III.2) carried the c.4325T.
C mutation from his father plus the reported pathogenic c.2167+
5G.A allele inherited from his mother. Haplotype analysis of the
pedigree confirmed cosegregation of these pathogenic variants
(Figure 3). In this family, the exceptional non-compliance with the
homozygosity-by-descent assumption had excluded USH2A as the
causative gene in the RD chip analysis.
The 9RE pedigree (Figure 2) showed an autosomal dominant
cone dystrophy. In this large cohort, the high genetic informativity
allowed us to exclude most candidates after the RD cosegregation
chip, and Sanger sequencing ruled out the few remaining genes.
Exome sequencing was then undertaken and identified a new
mutation in GUCY2D, c.2747T.C. This candidate had not been
previously considered because the SNP haplotype analysis showed
recombination within the 39 flanking region in one affected
member (IV 5). Although the selected SNPs are closely linked to
the genes to minimize it, recombination, however infrequent, may
occur and mislead the analysis.
RD-Chip Efficiency
Table 4 summarizes the percentage of complete molecular
diagnosis attained with the RD chip, categorized by inheritance
pattern and the number of samples available per family. Six
autosomal dominant families with at least 4 available samples (and
a minimum of three patients) were analyzed, yet only one family,
6ORG, (7 samples with three affected members) was successfully
diagnosed. Indeed, when dealing with dominant diseases, the main
drawback for successful diagnosis is the large number of samples
required to attain discriminative genetic informativity. In contrast,
in recessive families, the percentage of success doubles to 33% (6
out of 18) in non-consanguineous, and dramatically raises up to
80% (8 out of 10), in consanguineous pedigrees. We conclude that
the highest informativity of recessive pedigrees, particularly under
the homozygosity-by-descent assumption in consanguinity, in-
creases the efficiency of the RD chip and highlights its reliability
for RD molecular diagnosis.
Figure 3. Cosegregation of USH2A mutations identified in
family E5. Three heterozygous USH2A mutations cosegregate with the
disease in this consanguineous family. Patient II-4 carried two mutated
alleles M2 (c.4325T.C) and M3 (c.7364G.A), whereas his affected son
(III-2) inherited the M3 paternal allele plus the reported M1 (c.2167+
5G.A) mutation from his mother.
doi:10.1371/journal.pone.0088410.g003
Table 4. Families solved by the RD-chip according to the number of samples available and the inheritance pattern.
Number of families solved/Total number of families
4 samples 5 samples 6 samples 7 samples 8 samples .8 samples Total
Dominants 0/1 0/1 1/2 0/2 1/6
Recessives 4/7* 2/6 0/1 0/2 0/1 0/1 6/18
Consanguineous 2/2 1/3 1/1 2/2 2/2 8/10
X-linked 1/1 1/1 2/2
Total 7/10 3/10 1/3 2/5 2/3 2/5 17/36
*One allel identified by direct genotiping in 3 cases.
doi:10.1371/journal.pone.0099354.t004
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Finally, two X-linked cohorts were successfully diagnosed. The
RD chip included markers for cosegregation analysis of the two
known X-linked causative loci (RP2 and RPGR), given that X-
linked inheritance can only be discarded in pedigrees with male-
to-male transmission [36], and as a means to avoid the
burdensome task of sequencing the hot-spot ORF15 of RPGR
whenever cosegregation analysis does not support it.
Discussion
To meet the increasing demand for genetic diagnosis from
clinicians and patients, we have devised and optimized an RD chip
that allows us to extract maximum genetic informativity from
pedigrees, exclude a large number of non-cosegregating candi-
dates and focus on the most probable causative genes. Moreover,
the exclusion of all analyzed candidates by the RD chip highlights
the families suitable for next generation sequencing (NGS) and
subsequent identification of novel RD genes.
To improve the efficiency and the scope of the RD-Chip with
respect previous attempts [12,37] we have: i) increased the number
of SNPs (7–10) per gene to maximize the genetic informativity, ii)
extended the cosegregation study to 100 retinal dystrophy genes,
and iii) included some prevalent pathogenic point mutations in the
Spanish population for direct genotyping. The RD-chip allows to
genotype 768 selected SNPs in a single cost- and time-effective step
and is designed to use on families, not on simplex cases.
With this optimized RD-chip version, 17 out of 36 Spanish
pedigrees have been fully diagnosed. Twelve new and 12
previously reported pathological variants have been identified in
9 RD genes, adding to the high genetic diversity in retinal
disorders. The fact that as much as half of the mutations identified
are new underscores the efficiency of our RD chip compared to
direct mutational screening., particularly in non-homogenous
genetic populations. Concerning the major candidates in our
cohort, CRB1 and USH2A explain 10/19 families overall, in
accordance with other reports [38,39] and consistent with their
contribution to several clinical entities. CRB1 is responsible for RP
and LCA (a more severe form of RP), and more than 150
mutations have been described so far (http://www.hgmd.org). In
our panel, the LCA pedigree (10RE) carried a novel splicing
mutation, whereas the RP pedigrees (12ORG, 23NCE, 25NCE,
T5) were all associated to missense variants (Table 1). Our results
agree with the CRB1-assigned phenotype-genotype correlations,
where null alleles are mainly associated to the LCA phenotype
[39,40]. Also in agreement with previous reports, p.C948Y is the
most prevalent CRB1 mutation in our family panel (3 of the 5
CRB1 families) [39].
Five non-syndromic RP families presented 4 new (2 missense,
one nonsense and one splicing mutation) and 7 reported (5
missense, one nonsense and one splicing mutation) pathogenic
alleles in USH2A. In the Usher cohorts, analysis of USH2A
rendered 2 new missense and 3 known (one frameshift and 2
missense) mutations. In two families, only one of the pathogenic
alleles was identified. In fact, some reports support that as much as
35% of the second USH2A mutant alleles are duplications,
deletions and deep intronic variants, which are extremely difficult
to detect by DNA sequencing [27]. On the other hand, no clear
phenotype-genotype correlation could be established between RP
and Usher cases. The most prevalent USH2A mutation in non-
syndromic RP, p.C759F [32,41], was also present in three families
of our cohort. Notably, double heterozygosis in USH2A was
unexpectedly found in two consanguineous families. In fact, in
pedigree E5, three pathogenic alleles were identified in two
generations. In this particular case, the assumption of homozy-
gosity by descent led us to wrongly assume non-cosegregation with
all RD genes and undertake WES analysis, which eventually
identified an unexpected double heterozygous genotype. A
seemingly higher number of mutation carriers had also been
reported for other syndromic RPs, such as Bardet-Biedl, with no
solid evidence for this finding [42].
The inclusion of X-linked markers in the RD-chip has proved to
be extremely useful to diagnose families compatible with both
autosomal and X-linked inheritance patterns. In fact, in pedigree
11NCE, the milder affectation of the female patients was already
suggestive of a pseudo-dominant effect, as it was indeed confirmed
(RP2 was the causative gene). On the other hand, family 20NCE,
with an unassigned mendelian pattern, cosegregated with X-linked
markers, which prompted to focus on the X-linked candidates. A
deletion comprising the RP2 locus was identified (Table 1).
Remarkably, the clinical heterogeneity of retinal disorders was
highlighted by the identification of RD3–up to now associated only
to LCA– as causative of RP (Table 1), increasing the phenotypes
associated to the gene mutations. This case would have remained
unassigned by conventional methods had it been not for the
comprehensive analysis of our RD chip, whose main asset is the
robustness of genetic information to highlight the most probable
candidates, avoiding the yet burdensome task of big data analysis.
Particularly, identification of shared (which indicate a common
founder effect) or extended haplotypes over closely mapping genes
(which strengthen cosegregation) are invaluable clues to directly
pinpoint the causative mutation, unveil unexpected candidates,
and/or prompt re-evaluation of clinical features.
Recently, a variety of NGS-based procedures have been
developed for molecular diagnosis of RDs, from targeted long-
Table 5. Comparison of efficiencies of different methods for RD molecular diagnosis.
N6 Genes analyzed Yield Reference
APEX 1-16 15-44% [44, 54]
Long-PCR 9 33% [43]
Autozygome 16-100 42-52% [48, 55]
Target Capture 105-179 36-56% [11, 44-47, 56]
WES All 44-83%* [43, 48, 49, 57]
WGS All 50% [10]
RD-chip 100 47% This study
*Higher efficiency percentages are obtained when few families or cases are analysed.
doi:10.1371/journal.pone.0099354.t005
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range PCR coupled to NGS [43,44], targeted capture and
sequencing of one or several RD genes [45–47], to full WES
analysis [11,48,49]. Although powerful tools, they still yield limited
complete diagnostic success: from 37%–52% in non-related
cohorts to 80% in cohorts with high consanguinity levels [48]
(Table 5). Aside high costs, the restraints of NGS-targeted
approaches are due to the high genetic heterogeneity of retinal
disorders, whereas the main drawbacks of WES are the high
sequence coverage requirement and the functional interpretation
of the identified variants (WES). Within this context, the RD-chip
efficiency ranges from 16% in dominant to 80% in consanguin-
eous recessive pedigrees, with an average of 47%, well within the
upper range of the NGS approaches. Besides, the design of this
chip is extremely flexible, which allows to incorporate new SNPs to
expand the gene repertoire after new discoveries or upon demand.
Before NGS paves the future of personalized diagnosis, our cost-
and time-effective strategy allows a quick and reliable prioritiza-
tion of candidates, which is suitable and affordable for middle-size
diagnostic labs with moderate to high number of family cases.
Supporting Information
Figure S1 Cosegregation analysis of the novel muta-
tions identified. M: mutation
(TIF)
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